Poussot climbs at Wyeth
This article was originally published in The Tan Sheet
Executive Summary
Bernard Poussot adds chief operating officer and board member to his titles at the Madison, N.J.-based firm, where he was named president and vice chairman in April 2006. Wyeth says Jan. 26 Poussot, 55, will add to his responsibilities leadership of the Wyeth Consumer Healthcare and Fort Dodge Animal Health and continue to lead the firm's Pharmaceuticals and R&D divisions. Poussot, who will continue to report to Chairman and CEO Robert Essner, began his career at Wyeth in 1986; in 1996 he was appointed president of Wyeth-Ayerst International and in 1997 became president of the worldwide pharmaceutical business before rising in 2002 to executive VP for R&D...
You may also be interested in...
Wyeth names new CEO
Wyeth announced Sept. 27 that Bernard Poussot will assume the position of CEO and president as of Jan. 1, 2008. Poussot will replace Robert Essner, who was elected CEO in May 2001 and became chairman in January 2003. Poussot began his career at Wyeth in 1986, and held positions including executive vice president until January 2007, when he was promoted to president, chief operating officer and vice chairman of Wyeth (1"The Tan Sheet" Jan. 29, 2007, In Brief). Essner will remain in his positions at Wyeth until Poussot's Jan. 1 start-date...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.